U.S. Human Papillomavirus Testing Market (2025 - 2033)

Market Size & Trends

The U.S. human papillomavirus testing market size was estimated at USD 638.37 million in 2024 and is projected to grow at a CAGR of around 13.56% from 2025 to 2033. The market growth is propelled by evolving clinical guidelines, technological innovation, and growing emphasis on preventive healthcare. The U.S. Preventive Services Task Force (USPSTF) and American Cancer Society (ACS) recommend primary HPV testing or co-testing for women aged 30-65, boosting adoption. FDA approvals, such as Abbott’s Alinity m HR HPV assay (November 2023) and Roche’s cobas Human Papillomavirus (HPV) Test, have expanded high-sensitivity, genotype-specific options. Increasing self-sampling pilots, led by organizations like Kaiser Permanente, are improving screening access for underserved populations. Rising awareness campaigns from the CDC and American Sexual Health Association further drive demand, aligning with national goals to reduce cervical cancer incidence.

The U.S. HPV testing industry is undergoing rapid transformation, fueled by updated clinical guidelines, landmark regulatory approvals, and a shift toward patient-centered screening models. In July 2020, the American Cancer Society (ACS) updated its recommendations, making primary HPV testing every five years the preferred method for individuals aged 25-65, citing superior accuracy, longer screening intervals, and reduced unnecessary interventions compared with Pap smears. This move reflects growing evidence that HPV testing more reliably detects high-grade precancerous lesions while avoiding the overdiagnosis associated with cytology.

In December 2024, the U.S. Preventive Services Task Force (USPSTF) released draft guidelines recommending HPV testing every five years for women aged 30-65, with Pap testing or HPV/Pap co-testing as acceptable alternatives. Critically, the USPSTF included self-collected HPV samples taken in healthcare settings for the first time, acknowledging studies showing comparable accuracy to clinician-collected specimens and significantly higher uptake among historically underscreened groups.

A major regulatory milestone followed in May 2024, when the FDA approved HPV self-collection for cervical cancer screening in clinical environments. ACS CEO stated, “Self-collection can expand access to screening and reduce barriers, giving more people the opportunity to detect, treat, and ultimately survive cancer.” On the same day, Roche secured FDA approval for its cobas HPV self-collection solution, enabling patients to privately collect vaginal samples for laboratory testing. Roche Diagnostics CEO emphasized, “Our HPV self-collection solution helps support the goal of eliminating cervical cancer by 2030 by reducing barriers and providing access to HPV screening.”

With 13,000 new cervical cancer diagnoses and 4,000 related deaths annually in the U.S.-over half in underscreened populations-these combined initiatives are poised to close critical screening gaps. Public-private collaborations, such as the National Cancer Institute’s Cervical Cancer “Last Mile” Initiative, are aligning with WHO’s 2030 elimination strategy to expand reach, modernize screening pathways, and ensure equity in access. As adoption of self-collection and guideline-driven HPV testing accelerates, the U.S. HPV testing market is expected to see robust growth, driven by increased demand for high-sensitivity molecular assays, broader participation, and expanded reimbursement coverage.

Market Concentration & Characteristics

The U.S. HPV testing market demonstrates a high degree of innovation, marked by advancements in molecular diagnostics, extended genotyping, and self-collection technologies. FDA approvals like Roche’s cobas HPV self-collection solution (May 2024) and Abbott’s Alinity m HR HPV assay (November 2023) exemplify cutting-edge approaches that enhance accessibility, accuracy, and patient comfort. These innovations support guideline shifts toward primary HPV testing and are pivotal in meeting the WHO’s 2030 cervical cancer elimination goals.

The level of M&A in the U.S. human papillomavirus testing market is low, with most corporate activity happening at a broader women’s health or molecular diagnostics level rather than being HPV-focused. Large players like Hologic, Roche, Abbott, and BD are instead expanding through product launches, technology partnerships, and platform integration rather than direct acquisitions of HPV test businesses. Recent consolidation trends are seen more in global markets-such as H.U. Group Holdings’ acquisition of Hatch Healthcare’s HPV self-test service in Japan (Dec 2024)-than in the U.S., where growth is being driven by regulatory approvals, updated screening guidelines, and self-collection adoption rather than M&A.

Regulatory changes in the U.S. have had a direct and positive impact on HPV testing adoption, market access, and innovation. The FDA’s approval of HPV self-collection in healthcare settings on May 15, 2024, marked a pivotal moment, expanding screening options and enabling broader reach, particularly among underserved populations. This regulatory milestone aligns with updated American Cancer Society and U.S. Preventive Services Task Force guidelines that prioritize primary HPV testing every five years for individuals aged 25-65. These frameworks have accelerated the shift from Pap cytology to molecular HPV assays, driving demand for FDA-approved, high-sensitivity tests like Roche’s cobas and Abbott’s Alinity m HR HPV assay. Collectively, these regulations are increasing screening coverage, encouraging product innovation, and supporting the national goal of cervical cancer elimination by 2030.

Product expansion in the U.S. HPV testing industry is being driven by the integration of advanced molecular assays, extended genotyping, and self-collection solutions into existing diagnostic platforms. In November 2023, Abbott broadened its molecular diagnostics portfolio with FDA approval of the Alinity m HR HPV assay, enabling both primary screening and co-testing with detailed genotype risk stratification. In May 2024, Roche launched its FDA-approved cobas HPV self-collection solution, offering patients a private, in-clinic sampling option that maintains laboratory accuracy. Major players like Hologic are also enhancing multi-assay platforms such as the Panther System, allowing HPV testing to be run alongside other STI and women’s health tests, streamlining workflows and increasing lab efficiency. These expansions are improving test accessibility, accuracy, and throughput while aligning with evolving screening guidelines.

Regional expansion in the U.S. human papillomavirus testing market is focused on increasing access in underserved and rural areas, where screening rates remain below national targets. Large diagnostics providers such as Quest Diagnostics and Labcorp are extending HPV testing services through expanded laboratory networks, mobile health units, and partnerships with community health centers. Public-private collaborations, including state-level initiatives in Appalachia, the Deep South, and Native American reservations, are integrating FDA-approved self-collection options like Roche’s cobas HPV self-collection solution to overcome cultural, geographic, and economic barriers. These efforts not only expand geographic reach but also align with national cervical cancer elimination goals by increasing screening participation in high-need regions.

Application Insights

In 2024, cervical cancer screening dominated the U.S. human papillomavirus (HPV) testing market, capturing 77.90% of total revenue. This leadership stems from the high burden of HPV-related cervical cancer and the critical importance of early detection in preventing disease progression. Adoption is further supported by the availability of advanced, noninvasive testing methods, including HPV DNA assays and liquid-based cytology, which improve accuracy and patient comfort. Public health campaigns and government-backed screening initiatives have also played a central role in expanding access and boosting participation rates in cervical cancer prevention programs.

The vaginal cancer screening segment is forecast to expand at a strong CAGR of 11.47% from 2025 to 2033, driven by increased understanding of HPV’s contribution to vaginal cancer risk. Technological advances are enabling more precise detection, while education efforts are raising awareness of the benefits of early diagnosis. Identifying HPV infections at a precancerous stage supports timely treatment and reduces the likelihood of cancer development. Growth is further underpinned by improvements in healthcare infrastructure, especially in developing economies, and the integration of routine HPV testing into broader women’s health screening services.

Product Insights

In 2024, the consumables segment held the largest share of revenue in the U.S. human papillomavirus (HPV) testing industry, driven by rising demand for accurate, efficient, and cost-effective diagnostic tools. Essential items such as test kits, reagents, and cartridges remain integral to reliable HPV detection and screening, both of which are vital for cervical cancer prevention. The expansion of routine HPV testing in healthcare systems and the rollout of large-scale screening programs globally have further accelerated segment growth. Additionally, the ease of use and convenience of these products have strengthened their uptake across clinical settings.

The services segment is projected to post the fastest CAGR over the forecast period, supported by growing demand for specialized HPV testing and patient support services. Providers are increasingly offering comprehensive solutions that combine laboratory diagnostics with result interpretation, counseling, and educational resources. Rising awareness of HPV-related cancer risks, combined with public health initiatives encouraging regular screening, is fueling service demand. Continued advancements in molecular diagnostics and the adoption of personalized treatment strategies are expected to expand the scope, value, and impact of HPV-related services.

Technology Insights

In 2024, the PCR segment accounted for the largest revenue share of the U.S. human papillomavirus (HPV) testing market, supported by its exceptional sensitivity and accuracy in detecting HPV DNA. Polymerase Chain Reaction enables precise identification of specific viral strains, including high-risk types associated with cervical and other HPV-related cancers. Its capability to detect low viral loads at early stages of infection has established PCR as the preferred testing method. Additionally, its scalability, automation compatibility, and adaptability to various clinical settings have reinforced its leading position in the industry.

The immunodiagnostics segment is anticipated to register robust growth over the forecast period, driven by rising demand for reliable, cost-effective, and rapid diagnostic tools. By detecting HPV-specific antibodies or antigens, immunodiagnostic tests deliver high sensitivity with faster turnaround times, making them well-suited for large-scale screening initiatives. Growing awareness of the benefits of preventive healthcare and early detection, coupled with technological advancements and expanded testing infrastructure in emerging markets, is expected to further accelerate adoption and broaden the segment’s market presence.

End Use Insights

In 2024, the hospitals and clinics segment dominated the U.S. HPV testing market, reflecting their pivotal role in delivering comprehensive healthcare services. These facilities serve as the primary access points for HPV screening, offering advanced diagnostic equipment, skilled medical personnel, and integrated follow-up care. Their established trust among patients, combined with awareness campaigns encouraging regular screening, has reinforced their market leadership. The centralized infrastructure in hospitals and clinics enables efficient testing and timely intervention, further solidifying their position.

The laboratories segment is projected to witness strong growth over the forecast period, driven by increasing demand for precise, efficient, and high-throughput diagnostic solutions. Rising awareness of HPV-related cancer risks, coupled with advancements in molecular diagnostics such as PCR and next-generation sequencing, is enhancing testing accuracy and turnaround times. The growing prevalence of HPV infections and public health initiatives promoting widespread screening are expanding the role of laboratories, positioning them as a critical component in the HPV testing ecosystem.

Key U.S. Human Papillomavirus Testing Company Insights

Some of the key companies in the U.S. human papillomavirus testing industry include Abbott, bioMerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, and Siemens Healthineers AG.

• Abbott offers innovative healthcare solutions, including diagnostic tools, medical devices, nutrition products, and branded generic medicines. The company focuses on improving health and enhancing lives through cutting-edge technology and scientifically backed solutions worldwide.

• bioMérieux specializes in diagnostic solutions, offering a range of products and services for clinical microbiology, molecular biology, and immunoassays. Its solutions help detect infectious diseases, ensuring faster, more accurate diagnoses and better patient outcomes globally.

Recent Developments

• In April 2025, Quest Diagnostics announced a new initiative to expand access to human papillomavirus (HPV) screening for women at risk of developing cervical cancer. Under this program, physicians can now offer patients the choice to self-collect specimens for HPV screening in a clinical or other healthcare setting. Beginning early next month, Quest will also make the self-collection option, with a physician’s order, available at its 2,000 patient service centers nationwide. This initiative builds on Quest’s success with self-collection services introduced in October 2024 for vaginitis and other genital tract infections, including chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium, which have seen strong patient uptake. The new offering leverages Roche’s FDA-cleared HPV self-collection solution, approved in May 2024 for use with the cobas HPV test, enabling convenient and discreet sample collection while maintaining clinical accuracy.

• May 2024, Roche received FDA approval for one of the first HPV self-collection solutions in the U.S. This approval is expected to enhance access to screening and support efforts to eliminate cervical cancer. This solution allows for early detection of HPV, helping identify women at risk and enabling timely treatment to prevent cervical cancer development.

U.S. Human Papillomavirus Testing Market